Assessment of panobacumab as adjunctive immunotherapy for the treatment of nosocomial Pseudomonas aeruginosa pneumonia

No abstract is available for this paper.

• Publication year

  2014

• Venue

  European Journal of Clinical Microbiology and Infectious Diseases

• Publication date

  2014-05-24

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10096-014-2156-1PMID 24859907
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Infection Control in ICU

  2015cited by this paper
• Pseudomonas aeruginosa serotypes in nosocomial pneumonia: prevalence and clinical outcomes

  2014cited by this paper
• Impact of multidrug resistance on Pseudomonas aeruginosa ventilator-associated pneumonia outcome: predictors of early and crude mortality

  2013cited by this paper
• 10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America.

  2013cited by this paper
• Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT International Cohort Study

  2012cited by this paper
• Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: A randomized,double-blind, placebo-controlled trial*

  2012cited by this paper
• Anti-Pseudomonas aeruginosa serotype O11 LPS immunoglobulin M monoclonal antibody panobacumab (KBPA101) confers protection in a murine model of acute lung infection.

  2011cited by this paper
• Risk Factors for Development of Intestinal Colonization with Imipenem-Resistant Pseudomonas aeruginosa in the Intensive Care Unit Setting

  2011cited by this paper
• Monoclonal antibodies in infectious diseases: clinical pipeline in 2011.

  2011cited by this paper
• Ahlstrand E , Persson L , Tidefelt U , Söderquist B. Alteration of the colonization pattern of coagulase-negative staphylococci in patients undergoing treatment for hematological malignancy. Eur J Clin Microbiol Infect Dis

  2011cited by this paper
• Polyclonal immunoglobulins and hyperimmune globulins in prevention and management of infectious diseases.

  2011cited by this paper
• Pharmacokinetics and safety of panobacumab: specific adjunctive immunotherapy in critical patients with nosocomial Pseudomonas aeruginosa O11 pneumonia.

  2011influential reference
• Relative contribution of three main virulence factors in Pseudomonas aeruginosa pneumonia*

  2011cited by this paper
• Antibiotic exposure and resistance development in Pseudomonas aeruginosa and Enterobacter species in intensive care units*

  2011cited by this paper
• Preclinical In Vitro and In Vivo Characterization of the Fully Human Monoclonal IgM Antibody KBPA101 Specific for Pseudomonas aeruginosa Serotype IATS-O11

  2010cited by this paper
• Other therapeutic modalities and practices: implications for clinical trials of hospital-acquired or ventilator-associated pneumonia.

  2010cited by this paper
• International study of the prevalence and outcomes of infection in intensive care units.

  2009cited by this paper
• International study of the prevalence and outcomes of infection in intensive care units

  2009cited by this paper
• Ventilator-associated pneumonia caused by multidrug-resistant organisms or Pseudomonas aeruginosa: prevalence, incidence, risk factors, and outcomes.

  2008cited by this paper
• Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: A systematic review and meta‐analysis *

  2007cited by this paper
• Association patterns of Pseudomonas aeruginosa clinical isolates as revealed by virulence traits, antibiotic resistance, serotype and genotype.

  2007influential reference
• Autoantibodies against bactericidal/permeability–increasing protein (BPI–ANCA) in cystic fibrosis patients treated with azithromycin

  2005cited by this paper
• Resolution of ventilator-associated pneumonia: Prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome*

  2003cited by this paper
• O-Antigen Serotypes and Type III Secretory Toxins in Clinical Isolates of Pseudomonas aeruginosa

  2003influential reference
• Pseudomonas aeruginosa ventilator-associated pneumonia: comparison of episodes due to piperacillin-resistant versus piperacillin-susceptible organisms.

  2002cited by this paper
• Human Monoclonal Antibodies againstPseudomonas aeruginosa Lipopolysaccharide Derived from Transgenic Mice Containing Megabase Human Immunoglobulin Loci Are Opsonic and Protective against Fatal Pseudomonas Sepsis

  2001cited by this paper
• Cytokine modifiers: pipe dream or reality?

  1998cited by this paper
• Serotyping and virulence factors of Pseudomonas aeruginosa clinical isolates.

  1997cited by this paper
• The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure

  1996cited by this paper
• The effect of late-onset ventilator-associated pneumonia in determining patient mortality.

  1995cited by this paper
• Effect of high-affinity anti-Pseudomonas aeruginosa lipopolysaccharide antibodies induced by immunization on the rate of Pseudomonas aeruginosa infection in patients with cystic fibrosis.

  1995cited by this paper
• Prophylactic intravenous administration of standard immune globulin as compared with core-lipopolysaccharide immune globulin in patients at high risk of postsurgical infection.

  1992cited by this paper
• Immunoprotective human monoclonal antibodies against five major serotypes of Pseudomonas aeruginosa.

  1987cited by this paper
• APACHE II: A severity of disease classification system

  1985cited by this paper
• Infectious Diseases Society of America

  1969cited by this paper

• A monoclonal antibody raised against Acinetobacter baumannii capsular carbohydrate exhibits cross-species in vitro binding against Pseudomonas aeruginosa

  2026influential citation
• Current and future options for the treatment of serious infections due to carbapenem-resistant Pseudomonas aeruginosa

  2025cites this paper
• Immune system dynamics in response to Pseudomonas aeruginosa biofilms

  2025cites this paper
• Beyond Antibiotics: Emerging Therapies for Pseudomonas aeruginosa in Diabetic Foot Infections.

  2025cites this paper
• Current Management Strategies of Difficult-to-Treat Resistant Pseudomonas aeruginosa Infections.

  2025cites this paper
• Antibiotic conjugates: Using molecular Trojan Horses to overcome drug resistance.

  2025cites this paper
• Decoding antibiotic resistance in Pseudomonas aeruginosa: Embracing innovative therapies beyond conventional antibiotics

  2025cites this paper
• Understanding the pathophysiology of Pseudomonas aeruginosa colonization as a guide for future treatment for chronic leg ulcers

  2025cites this paper
• Antibacterial agents active against Gram Negative Bacilli in phase I, II, or III clinical trials

  2024cites this paper
• Monoclonal Antibody Therapies for Infectious Diseases.

  2024cites this paper
• Microbiota and Immunity during Respiratory Infections: Lung and Gut Affair

  2024cites this paper
• Clinical assays rapidly predict bacterial susceptibility to monoclonal antibody therapy

  2024cites this paper
• Anti-Pseudomonas aeruginosa Vaccines and Therapies: An Assessment of Clinical Trials

  2023cites this paper
• Alternative therapeutic strategies to treat antibiotic-resistant pathogens

  2023cites this paper
• Therapeutic Antibodies in Medicine

  2023cites this paper
• Are monoclonals the way forward to prevent or to treat ventilator-associated pneumonia in the intensive care unit?

  2023cites this paper
• Efficacy of a Pseudomonas aeruginosa serogroup O9 vaccine

  2023cites this paper
• Monoclonal antibodies against lipopolysaccharide protect against Pseudomonas aeruginosa challenge in mice

  2023cites this paper
• Pseudomonas aeruginosa: Infections and novel approaches to treatment “Knowing the enemy” the threat of Pseudomonas aeruginosa and exploring novel approaches to treatment

  2023cites this paper
• Monoclonal antibodies for prophylaxis and therapy of respiratory syncytial virus, SARS-CoV-2, human immunodeficiency virus, rabies and bacterial infections: an update from the World Association of Infectious Diseases and Immunological Disorders and the Italian Society of Antinfective Therapy

  2023cites this paper
• Recent Advances in Monoclonal Antibody-Based Approaches in the Management of Bacterial Sepsis

  2023cites this paper
• Novel investigational treatments for ventilator-associated pneumonia and critically ill patients in the intensive care unit

  2022cites this paper
• Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial

  2022cites this paper
• The threat of multidrug-resistant/extensively drug-resistant Gram-negative respiratory infections: another pandemic

  2022cites this paper
• Engineering the supernatural: monoclonal antibodies for challenging infectious diseases

  2022cites this paper
• Novel antimicrobial agents for combating antibiotic-resistant bacteria.

  2022cites this paper
• Microbiome Modulation as a Novel Strategy to Treat and Prevent Respiratory Infections

  2022cites this paper
• Therapeutic Antibodies for the Treatment of Respiratory Tract Infections—Current Overview and Perspectives

  2021cites this paper
• Antimicrobial immunotherapeutics: past, present and future.

  2021cites this paper
• Pneumonia

  2021cites this paper
• Immunization and Immunotherapy Approaches against Pseudomonas aeruginosa and Burkholderia cepacia Complex Infections

  2021cites this paper
• Pneumonies associées aux soins de réanimation* RFE commune SFAR–SRLF

  2019cites this paper
• Infections by multidrug-resistant Gram-negative Bacteria: What's new in our arsenal and what's in the pipeline?

  2019cites this paper
• Multidrug-Resistant Bacteria and Alternative Methods to Control Them: An Overview

  2019cites this paper
• Where are we with monoclonal antibodies for multidrug-resistant infections?

  2019cites this paper
• Drug Prevention and Control of Ventilator-Associated Pneumonia

  2019cites this paper
• Mechanistic research holds promise for bacterial vaccines and phage therapies for Pseudomonas aeruginosa

  2019cites this paper
• Recombinant production of the complex human IgM-Evaluation of variations in quality attributes

  2019cites this paper
• Considerations and Caveats in Combating ESKAPE Pathogens against Nosocomial Infections

  2019cites this paper
• Mechanistic research holds promise for bacterial vaccines and phage therapies for Pseudomonas aeruginosa

  2019cites this paper
• Пригнічення бактеріальних факторів вірулентності як метод лікування бактеріальних пневмоній

  2018cites this paper
• Monoclonal antibodies as anti-infective products: a promising future?

  2018cites this paper
• 23rd International Symposium on Infections in the Critically Ill Patient

  2018cites this paper
• Therapeutic antibodies: A new era in the treatment of respiratory diseases?

  2018cites this paper
• The New Versus Old Target Debate for Drug Discovery

  2018cites this paper
• Healthcare associated pneumonia in the intensive care unit

  2018cites this paper
• CAL02 Liposomes and Other Antitoxins: A New Generation of Anti-Infectives

  2018cites this paper
• Principles of Immunotherapy: Implications for Treatment Strategies in Cancer and Infectious Diseases

  2018cites this paper
• Progress Toward the Elusive Pseudomonas aeruginosa Vaccine

  2018cites this paper
• Is Zero Ventilator-Associated Pneumonia Achievable?: Practical Approaches to Ventilator-Associated Pneumonia Prevention.

  2018cites this paper
• Pharmacokinetic and Pharmacodynamic Considerations for the Use of Monoclonal Antibodies in the Treatment of Bacterial Infections

  2018cites this paper
• Pneumonies associées aux soins de réanimation

  2018cites this paper
• The research agenda in VAP/HAP: next steps

  2017cites this paper
• Anti-bacterial Monoclonal Antibodies.

  2017cites this paper
• A New Take on an Old Remedy: Generating Antibodies against Multidrug-Resistant Gram-Negative Bacteria in a Postantibiotic World

  2017cites this paper
• Emerging Themes in Drug Resistance

  2017cites this paper
• Hospital-acquired pneumonia in ICU.

  2017cites this paper
• Recombinant Antibodies for Infectious Diseases

  2017influential citation
• New Strategies Targeting Virulence Factors of Staphylococcus aureus and Pseudomonas aeruginosa

  2017cites this paper
• Bacteria in the respiratory tract-how to treat? Or do not treat?

  2016cites this paper
• Investigational drugs in phase I and phase II clincial trials for the treatment of hospital-acquired pneumonia

  2016cites this paper
• Therapeutic monoclonal antibodies for respiratory diseases: Current challenges and perspectives, March 31 – April 1, 2016, Tours, France

  2016cites this paper
• Advances in antibiotic therapy in the critically ill

  2016cites this paper
• Precision medicine for the treatment of severe pneumonia in intensive care

  2016cites this paper
• Alternatives to antibiotics

  2016cites this paper
• Vaccines for Antibiotic-Resistant Bacteria: Possibility or Pipe Dream?

  2016cites this paper
• The SAATELLITE and EVADE Clinical Studies Within the COMBACTE Consortium: A Public-Private Collaborative Effort in Designing and Performing Clinical Trials for Novel Antibacterial Drugs to Prevent Nosocomial Pneumonia.

  2016cites this paper
• Promises and pitfalls for recombinant oligoclonal antibodies-based therapeutics in cancer and infectious disease

  2016cites this paper
• Nouvelles stratégies dans la prise en charge: Infections complexes en médecine intensive

  2015cites this paper
• Ventilator-associated Pneumonia Prevention. Is It Worth It?

  2015cites this paper
• Predicting the Outcomes of Subjects With Severe Community-Acquired Pneumonia Using Monocyte Human Leukocyte Antigen-DR

  2015cites this paper
• Antibacterial monoclonal antibodies: the next generation?

  2015influential citation
• New targets for new therapeutic approaches

  2014cites this paper